Barclays Lifts Amgen Price Target to $380

Amgen's price target has been raised to $380 from $360 by Barclays.

This move suggests that analysts at the investment firm are optimistic about the biotech company's future prospects.

The backtested results, which are not indicative of actual performance, show a potential increase in value for Amgen investors.

However, it is essential to note that backtesting has its limitations and may not reflect actual trading or economic factors.